甘精胰岛素与胰升血糖素样肽-1类似物治疗2型糖尿病的临床分析  

Clinical analysis of glargine and GLP-1 analogue in the treatment of type 2 diabetes mellitus

作　　者：牛永青 梁丽丽 

机构地区：[1]博兴县第二人民医院普内科,山东256504

出　　处：《国际医药卫生导报》2017年第10期1581-1583,共3页International Medicine and Health Guidance News

摘　　要：目的探讨2型糖尿病患者采用甘精胰岛素与胰升血糖素样肽-1类似物治疗的临床效果。方法选取本院门诊2014年1月至2016年1月收治的2型糖尿病患者118例，随机将其分为对照组59例与研究组59例，两组患者均以口服二甲双胍为基础治疗，对照组患者联用甘精胰岛素，研究组患者联合给予胰升血糖素样肽-1药物利拉鲁肽，比较两组患者的血糖控制效果、体重指数（BMI）、胰岛素抵抗指数（HOMA—IR）、不良反应以及用药成本一效果。结果研究组患者治疗后平均BMI为（27．0±1．3）kg／m。，平均HOMA—IR为（1．6±0．9），临床用药成本效果为（5161．5±14．6），均明显好于对照组，两组比较差异均有统计学意义（均P〈0．05），但两组患者治疗后不良反应发生率（5．2％比6．8％）比较差异无统计学意义（P〉0．05）。结论胰升血糖素样肽-1治疗2型糖尿病患者的临床效果明显好于甘精胰岛素，具有确切应用价值。Objective To investigate the clinical effect ofglargine and GLP-1 analogue in the treatment of type 2 diabetes mellitus. Methods 118 patients with type 2 diabetes mellitus in our hospital from January 2014 to January 2016 were selected, and randomly divided into control group （59 cases） and study group （59 cases）. The patients of two groups were treated with oral metformin. On the basis, the patients in control group were treated with glargine, while the patients in study group were treated with GLP- 1 analogue （Liraglutide）. The control effect of blood glucose, BMI, HOMA-IR, adverse reactions, and cost-effectiveness were compared between the two groups. Results In the study group, the BMI after treatment was （27.0±1.3）kg/m^2, the HOMA-IR was （1.6±0.9）, the cost-effectiveness of clinical medication was （5 161.5±14.6）, significantly better than those in the control group, with statistically significant differences （P〈0.05）. But there was no statistically significant difference in the incidence of adverse reactions between the two groups （5.2% vs.6.8%, P〉0.05）. Conclusion Clinical efficacy of

关 键 词：2型糖尿病 甘精胰岛素 胰升血糖素样肽-1 

分 类 号：R587.1[医药卫生—内分泌]